Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Pediatric acute GVHD: clinical phenotype and response to upfront steroids.

MacMillan ML, Holtan SG, Rashidi A, DeFor TE, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Sep 2. doi: 10.1038/s41409-019-0651-9. [Epub ahead of print]

PMID:
31477785
2.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

3.

Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.

Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML.

Biol Blood Marrow Transplant. 2019 Jul 17. pii: S1083-8791(19)30449-5. doi: 10.1016/j.bbmt.2019.07.017. [Epub ahead of print]

PMID:
31325587
4.

Validation of Minnesota acute graft-versus-host disease Risk Score.

MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ.

Haematologica. 2019 Jul 18. pii: haematol.2019.220970. doi: 10.3324/haematol.2019.220970. [Epub ahead of print]

5.

Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.

Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30326-X. doi: 10.1016/j.bbmt.2019.05.015. [Epub ahead of print]

PMID:
31128328
6.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ.

Blood Adv. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.

7.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
8.

Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.

Rashidi A, Shanley R, Holtan SG, MacMillan ML, Blazar BR, Khoruts A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2190-2196. doi: 10.1016/j.bbmt.2018.06.036. Epub 2018 Jul 7.

PMID:
30454871
9.

Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Amin K, Yaqoob U, Schultz B, Vaughn BP, Khoruts A, Howard JR, DeFor TE, Forster C, Meyer C, Gandhi I, Weisdorf DJ, Rashidi A, MacMillan ML, Blazar BR, Panoskaltsis-Mortari A, Holtan SG.

Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.

PMID:
30425334
10.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2019 Jan;25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018 Aug 25.

PMID:
30153491
11.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

12.

Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.

Keklik F, Alrawi EB, Cao Q, Bejanyan N, Rashidi A, Lazaryan A, Arndt P, Dincer EH, Bachanova V, Warlick ED, MacMillan ML, Arora M, Miller J, Brunstein CG, Weisdorf DJ, Ustun C.

Haematologica. 2018 Dec;103(12):2109-2115. doi: 10.3324/haematol.2018.189134. Epub 2018 Aug 3.

13.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW.

Blood Adv. 2018 May 8;2(9):1022-1031. doi: 10.1182/bloodadvances.2017013052. Erratum in: Blood Adv. 2018 Jun 12;2(11):1294.

14.

Elevations in serum alpha fetoprotein levels in patients with Fanconi anaemia.

Salem B, Mitchell R, DeFor TE, Tryon R, Wagner JE, MacMillan ML.

Br J Haematol. 2019 Mar;184(6):1032-1035. doi: 10.1111/bjh.15223. Epub 2018 Apr 20. No abstract available.

PMID:
29676781
15.

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.

Ebens CL, DeFor TE, Tryon R, Wagner JE, MacMillan ML.

Biol Blood Marrow Transplant. 2018 Apr;24(4):765-771. doi: 10.1016/j.bbmt.2017.11.031. Epub 2017 Dec 2.

16.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

17.

Human in vitro-induced regulatory T cells display Dlgh1dependent and PKC-θ restrained suppressive activity.

Zanin-Zhorov A, Kumari S, Hippen KL, Merkel SC, MacMillan ML, Blazar BR, Dustin ML.

Sci Rep. 2017 Jun 26;7(1):4258. doi: 10.1038/s41598-017-04053-5.

18.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.

19.

Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease.

Mehta RS, Cao Q, Holtan S, MacMillan ML, Weisdorf DJ.

Bone Marrow Transplant. 2017 Aug;52(8):1180-1186. doi: 10.1038/bmt.2017.90. Epub 2017 May 15.

20.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

21.

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.

Khandelwal P, Millard HR, Thiel E, Abdel-Azim H, Abraham AA, Auletta JJ, Boulad F, Brown VI, Camitta BM, Chan KW, Chaudhury S, Cowan MJ, Angel-Diaz M, Gadalla SM, Gale RP, Hale G, Kasow KA, Keating AK, Kitko CL, MacMillan ML, Olsson RF, Page KM, Seber A, Smith AR, Warwick AB, Wirk B, Mehta PA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1342-1349. doi: 10.1016/j.bbmt.2017.04.018. Epub 2017 Apr 24.

22.

Fanconi anemia: correlating central nervous system malformations and genetic complementation groups.

Johnson-Tesch BA, Gawande RS, Zhang L, MacMillan ML, Nascene DR.

Pediatr Radiol. 2017 Jun;47(7):868-876. doi: 10.1007/s00247-017-3817-x. Epub 2017 Mar 10.

PMID:
28283722
23.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.

Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12.

24.

Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Ebens CL, MacMillan ML, Wagner JE.

Expert Rev Hematol. 2017 Jan;10(1):81-97. doi: 10.1080/17474086.2016.1268048. Epub 2016 Dec 21. Review.

25.

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.

He F, Verneris MR, Cooley S, Blazar BR, MacMillan ML, Newell LF, Panoskaltsis-Mortari A, DeFor T, Weisdorf DJ, Holtan SG.

Bone Marrow Transplant. 2017 Feb;52(2):301-303. doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21. No abstract available.

26.

Phenotypic variability in patients with Fanconi anemia and biallelic FANCF mutations.

Tryon R, Zierhut H, MacMillan ML, Wagner JE.

Am J Med Genet A. 2017 Jan;173(1):260-263. doi: 10.1002/ajmg.a.37998. Epub 2016 Oct 7.

PMID:
27714961
27.

CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.

Osborn M, Lonetree CL, Webber BR, Patel D, Dunmire S, McElroy AN, DeFeo AP, MacMillan ML, Wagner J, Balzar BR, Tolar J.

Stem Cells Dev. 2016 Oct;25(20):1591-1603. Epub 2016 Aug 18.

28.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

29.

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM.

Haematologica. 2016 Oct;101(10):1190-1199. Epub 2016 Jul 14.

30.

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JH, Auletta J, Komanduri KV, Lindemans C, Riches ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1636-1645. doi: 10.1016/j.bbmt.2016.06.012. Epub 2016 Jun 22.

31.

Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation.

Barnum JL, Petryk A, Zhang L, DeFor TE, Baker KS, Steinberger J, Nathan B, Wagner JE, MacMillan ML.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1487-1492. doi: 10.1016/j.bbmt.2016.05.004. Epub 2016 May 12.

32.

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.

Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.

Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.

33.

Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia.

Donovan FX, Kimble DC, Kim Y, Lach FP, Harper U, Kamat A, Jones M, Sanborn EM, Tryon R, Wagner JE, MacMillan ML, Ostrander EA, Auerbach AD, Smogorzewska A, Chandrasekharappa SC.

Hum Mutat. 2016 May;37(5):465-8. doi: 10.1002/humu.22962. Epub 2016 Feb 23.

34.

Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.

Knorr DA, Wang H, Aurora M, MacMillan ML, Holtan SG, Bergerson R, Cao Q, Weisdorf DJ, Cooley S, Brunstein C, Miller JS, Wagner JE, Blazar BR, Verneris MR.

Biol Blood Marrow Transplant. 2016 May;22(5):825-33. doi: 10.1016/j.bbmt.2016.01.003. Epub 2016 Jan 13.

35.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, Brunstein C, Bejanyan N, Arora M.

Biol Blood Marrow Transplant. 2016 May;22(5):879-83. doi: 10.1016/j.bbmt.2015.12.020. Epub 2015 Dec 29.

36.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

37.

A risk-adapted approach to acute GVHD treatment: are we there yet?

Holtan SG, MacMillan ML.

Bone Marrow Transplant. 2016 Feb;51(2):172-5. doi: 10.1038/bmt.2015.261. Epub 2015 Nov 9. Review.

PMID:
26551780
38.

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan ML, Ustun C, Verneris MR, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE.

Biol Blood Marrow Transplant. 2016 Mar;22(3):487-92. doi: 10.1016/j.bbmt.2015.09.025. Epub 2015 Sep 30.

39.

Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.

Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M.

Biol Blood Marrow Transplant. 2016 Jan;22(1):134-40. doi: 10.1016/j.bbmt.2015.09.008. Epub 2015 Sep 11.

40.

Alternative donor hematopoietic cell transplantation for Fanconi anemia.

MacMillan ML, DeFor TE, Young JA, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE.

Blood. 2015 Jun 11;125(24):3798-804. doi: 10.1182/blood-2015-02-626002. Epub 2015 Mar 30.

41.

Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1029-36. doi: 10.1016/j.bbmt.2015.02.018. Epub 2015 Mar 7.

42.

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG.

Biol Blood Marrow Transplant. 2015 May;21(5):926-33. doi: 10.1016/j.bbmt.2015.01.023. Epub 2015 Feb 3.

43.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ.

Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.

44.

Bone mineral density in children with fanconi anemia after hematopoietic cell transplantation.

Petryk A, Polgreen LE, Barnum JL, Zhang L, Hodges JS, Baker KS, Wagner JE, Steinberger J, MacMillan ML.

Biol Blood Marrow Transplant. 2015 May;21(5):894-9. doi: 10.1016/j.bbmt.2015.01.002. Epub 2015 Jan 13.

45.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.

46.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT.

Blood. 2014 Nov 20;124(22):3221-7; quiz 3335. doi: 10.1182/blood-2014-06-577023. Epub 2014 Aug 28.

47.

Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes.

Flynn EK, Kamat A, Lach FP, Donovan FX, Kimble DC, Narisu N, Sanborn E, Boulad F, Davies SM, Gillio AP 3rd, Harris RE, MacMillan ML, Wagner JE, Smogorzewska A, Auerbach AD, Ostrander EA, Chandrasekharappa SC.

Hum Mutat. 2014 Nov;35(11):1342-53. doi: 10.1002/humu.22680.

48.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH.

Blood. 2014 Aug 21;124(8):1372-7. doi: 10.1182/blood-2014-04-567164. Epub 2014 Jun 30.

49.

Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation.

Forlenza GP, Polgreen LE, Miller BS, MacMillan ML, Wagner JE, Petryk A.

Pediatr Blood Cancer. 2014 Jun;61(6):1142-3. doi: 10.1002/pbc.24910. Epub 2013 Dec 24. No abstract available.

50.

Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.

Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR.

Bone Marrow Transplant. 2014 Feb;49(2):174-8. doi: 10.1038/bmt.2013.171. Epub 2013 Nov 4.

PMID:
24185590

Supplemental Content

Loading ...
Support Center